Log in to search using one of your social media accounts:


Researchers Discover Link between Gut Bacteria and the Effectiveness of Certain Cancer Drugs; Knowledge May Lead to New Types of Clinical Laboratory Tests

Microbiome is once again leading scientists toward a new understanding of how human gut bacteria can impact the efficacy and side-effects of certain cancer therapies Anatomic pathology researchers already know that a person’s genetics can affect the results of cancer treatments. Now it is becoming clear that a patient’s microbiome—which includes gut bacteria—may also impact […]
Source: Dark Daily - Category: Laboratory Medicine Authors: Tags: Instruments & Equipment Laboratory Instruments & Laboratory Equipment Laboratory Management and Operations Laboratory News Laboratory Pathology Laboratory Testing Albert Einstein College of Medicine anatomic pathology beta-glucuronidase Source Type: news

Related Links:

Chem. Commun., 2018, Advance Article DOI: 10.1039/C7CC08517F, CommunicationPoulami Majumder, Sukanya Bhunia, Arabinda Chaudhuri A tissue infiltrating peptide amphiphile-decorated nano-assembly induces significant mouse tumor growth inhibitionvia substantial tumor infiltration of encapsulated anti-angiogenic siRNA. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - Category: Chemistry Authors: Source Type: research
Conclusion Overall, the data indicates that OP-D may abrogate diverse signaling cascades linked to tumorigenesis, and can be used in combination with chemotherapeutic agents for cancer therapy. Graphical abstract
Source: Phytomedicine - Category: Drugs & Pharmacology Source Type: research
AbstractEarly preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy given that activation of the PD-1/PD-L1 axis putatively served as a mechanism for tumor evasion of host tumor antigen-specific T-cell immunity. Early-phase studies investigating several humanized monoclonal IgG4 antibodies targeting PD-1 and PD-L1 in advanced solid tumors paved way for the development of the first PD-1 inhibitors, nivolumab and pembrolizumab, approved by the Food and Drug Administration (FDA) in 2014. The number of FDA-approv...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Celgene has gone “all-in” on CAR-T cancer therapies, forking out $9 billion to acquire Juno Therapeutics amid much fanfare. Critics worry this wager may fail to help the biotech giant fill the gaps in its revenue stream.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: NASDAQ:CELG NASDAQ:GILD NASDAQ:JUNO Source Type: news
Nano LettersDOI: 10.1021/acs.nanolett.7b05292
Source: Nano Letters - Category: Nanotechnology Authors: Source Type: research
(Reuters) - Celgene Corp announced a $9 billion cash buyout of Juno Therapeutics Inc on Monday as it moves to cement its position as a key player in a new range of cancer therapies.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
(Wiley) Gene editing is one of the hottest topics in cancer research. A Chinese research team has now developed a gold-nanoparticle-based multifunctional vehicle to transport the 'gene scissors' to the tumor cell genome. As the authors report in the journal Angewandte Chemie, their nonviral transport and release platform of gene-editing systems has the additional advantage of combining hyperthermal cancer therapy with genetic modification.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
(Ecole Polytechnique F é d é rale de Lausanne) Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
This study revealed that the SALL4 ‐ KHDRBS3 network augments stemness through modulation of CD44 splicing in basal‐like breast cancer. This network enhances anoikis resistance for stemness. This study may contribute to the establishment of therapies targeting cancer stemness.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
Authors: Doan NB, Alhajala H, Al-Gizawiy MM, Mueller WM, Rand SD, Connelly JM, Cochran EJ, Chitambar CR, Clark P, Kuo J, Schmainda KM, Mirza SP Abstract Glioblastoma remains the most common, malignant primary cancer of the central nervous system with a low life expectancy and an overall survival of less than 1.5 years. The treatment options are limited and there is no cure. Moreover, almost all patients develop recurrent tumors, which typically are more aggressive. Therapeutically resistant glioblastoma or glioblastoma stem-like cells (GSCs) are hypothesized to cause this inevitable recurrence. Identifying prognost...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Laboratory Medicine | Pathology